Value Creators: Revenio
Translation: Original report published in Finnish on 10/1/2024 at 12:15 noon EEST.
In the Value Creators concept, we highlight companies that have created substantial shareholder value. The reports do not include forecasts; they are based solely on historical data and key figures derived from it.
We evaluate companies based on the following indicators:
- Revenue development
- Operating profit development and profitability (%)
- Return on capital (%)
- Cash flow generated from operations
- Share price development and historical valuations
- Data is primarily sourced from Bloomberg
We look at the long-term development and all figures are presented with the time series 2014-2023. The reports do not constitute investment recommendations.
In this report, we introduce Revenio - a global leader in ophthalmic equipment and software solutions, with a focus on eye care solutions.
Login required
This content is only available for logged in users
Revenio Group
34.7
32
Accumulate
Revenio is a medical technology company. Within the Group, there is research and development of pressure measurement technology that is used in the treatment of a number of diseases such as glaucoma, osteoporosis, skin cancer, and asthma. Operations are held worldwide and are run via most subsidiaries, each with a business focus. The company's head office is located in Vantaa.
Read more on company pageKey Estimate Figures08.08.
| 2023 | 24e | 25e | |
|---|---|---|---|
| Revenue | 96.6 | 105.2 | 120.9 |
| growth-% | -0.45 % | 8.90 % | 14.97 % |
| EBIT (adj.) | 28.5 | 28.6 | 36.9 |
| EBIT-% (adj.) | 29.53 % | 27.16 % | 30.55 % |
| EPS (adj.) | 0.80 | 0.83 | 1.09 |
| Dividend | 0.38 | 0.40 | 0.57 |
| Dividend % | 1.51 % | 1.47 % | 2.11 % |
| P/E (adj.) | 31.50 | 32.50 | 24.69 |
| EV/EBITDA | 22.03 | 21.94 | 16.92 |
Forum discussions
